Axinn Attorneys Named to Best Lawyers 2023
August 18, 2022
Axinn is pleased to announce that eight attorneys have been named to the 2023 list of “Best Lawyers in America” and five attorneys have been named to the list of “Ones to Watch.” Two attorneys have been named “Lawyer of the Year” in their individual practice areas. Each year, Best Lawyers®partners with U.S. News & World Report, the leading rankings publication in the United States to rank law firms and attorneys across the country. Best Lawyers®compiles their lists of outstanding attorneys by conducting peer-review surveys in which tens of thousands of leading lawyers confidentially evaluate their professional peers.
Antitrust Law
Stephen Axinn
Lisl Dunlop
John Harkrider
Michael Keeley
Litigation – Antitrust
Mark Alexander
Stephen Axinn
Lisl Dunlop
John Harkrider (Lawyer of the Year)
Michael Keeley
Litigation – Commercial
Francis Morrison III
Litigation – Intellectual Property
Matthew Becker
Francis Morrison III
Litigation – Insurance
Thomas Rohback
Litigation – Patent
Matthew Becker (Lawyer of the Year)
Francis Morrison III
Trade Secrets Law
Francis Morrison III
“Ones to Watch”
Rebecca Clegg: Intellectual Property Law, Litigation – Intellectual Property, Litigation – Patent
James Hunsberger: Antitrust Law
Kenina Lee: Antitrust Law, Litigation – Antitrust
Carol Xianxiao Liu: Antitrust Law
Lindsey Strang: Antitrust Law
To subscribe to our publications, click here.
Featured Insights
Featured Insights
ABA White Collar Crime Institute 2026
Speaking Engagement
GCR Live Cartels: 2026
Speaking Engagement
Antitrust
Noerr Competition Day 2026
Speaking Engagement
Antitrust
Consumer Brands CPG Legal Forum 2026
Speaking Engagement
NBA CLS 39th Annual Corporate Counsel Conference
Sponsorship
Antitrust
University of Pennsylvania Journal of Business Law Annual Symposium 2026
Speaking Engagement
Antitrust
No More Needles in Haystacks: Congress Requires FDA to Explain Q1/Q2 Sameness
Axinn Viewpoints
Intellectual Property
Oliver Twisted Again: After FDA's Court Losses, Congress Approves FDA's Standards on Orphan Drug Exclusivity
Axinn Viewpoints
Intellectual Property
2025 Healthcare Antitrust Enforcement Wrap Up
Axinn Viewpoints
Antitrust
Here We Go Again: Third Round of Inflation Reduction Act Drugs Listed
Axinn Viewpoints
Intellectual Property